Loading…
Reported covered position: Office of Representative Walter B. Jones (2006 - 2010); Office of Representative J.C. Watts (2002)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare IVIG Access Enhancement Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Medicare IVIG Access Enhancement Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Source: Senate LDA
| AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS |
| 13 |
| 2023–2026 |
| Legend Biotech Corporation | 11 | 2024–2026 |
| FEDERAL HEARINGS AND APPEALS SERVICES, INC. | 8 | 2025–2026 |
| OCHIN | 7 | 2021–2023 |
| AEROSPIKE INC. | 6 | 2023–2024 |
| CELLARES CORPORATION | 6 | 2025–2026 |
| CLICK THERAPEUTICS, INC. | 6 | 2025–2026 |
| CORETSU INC. | 6 | 2025–2026 |
| ALVOGEN, PHARMA US, INC. | 5 | 2023–2025 |
| CURRENT CLINIC INC. | 5 | 2025 |
| CHARACTER.AI | 4 | 2026 |
| CABALETTA BIO | 3 | 2025 |
| PALLADIAN PARTNERS, INC. | 3 | 2024–2025 |
| AMERICAN CLEANING INSTITUTE | 2 | 2021 |
| PEDIATRIC ASSOCIATES | 2 | 2025 |
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Medicare IVIG Access Enhancement Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Medicare IVIG Access Enhancement Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Preserving Patient Access to Home Infusion Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Preserving Patient Access to Home Infusion Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Preserving Patient Access to Home Infusion Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Preserving Patient Access to Home Infusion Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
John W. Walsh Alpha-1 Home Infusion Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
John W. Walsh Alpha-1 Home Infusion Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
John W. Walsh Alpha-1 Home Infusion Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
John W. Walsh Alpha-1 Home Infusion Act of 2025
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
John W. Walsh Alpha-1 Home Infusion Act of 2023
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS US LLP
H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma- derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.
Medicare IVIG Access Enhancement Act of 2023
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: HOGAN LOVELLS US LLP
H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma- derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.
H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma- derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.
Technology applications for legal and regulatory analysis.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Nuclear Regulatory Commission (NRC), Veterans Affairs, Dept of (VA)
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Represent the company in advocacy, including congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHARACTER.AI via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Issues concerning regulation of artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Patient access to biotechnology innovation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · third_quarter · Q3
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Technology applications for legal and regulatory analysis.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Office of Management & Budget (OMB), SENATE
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Represent the company in advocacy, including congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · 2T
Patient Access to digital health innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHARACTER.AI via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Issues concerning regulation of artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Patient access to biotechnology innovation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · second_quarter · Q2
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Technology applications for legal and regulatory analysis.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Represent the company in advocacy, including congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Patient Access to digital health innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHARACTER.AI via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Issues concerning regulation of artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Patient access to biotechnology innovation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · Q1
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHARACTER.AI via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2026 · first_quarter · RR
Issues concerning regulation of artificial intelligence technology
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · 4T
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Issues related to immigration policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRENT CLINIC INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Medicare payment for cardiac procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Patient Access to digital health innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Patient access to biotechnology innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · fourth_quarter · Q4
Technology applications for legal and regulatory analysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Patient access to biotechnology innovation
Filing targets: Defense, Dept of (DOD), Health & Human Services, Dept of (HHS)
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIC ASSOCIATES via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Advocate on access to pediatric medical care for children
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Issues related to immigration policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRENT CLINIC INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Medicare payment for cardiac procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Patient Access to digital health innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Technology applications for legal and regulatory analysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLARES CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · RR
Patient access to biotechnology innovation
CORETSU INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · RR
Technology applications for legal and regulatory analysis.
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · third_quarter · Q3
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: SENATE
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRENT CLINIC INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Medicare payment for cardiac procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Patient Access to digital health innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABALETTA BIO via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Cell and gene therapy innovation and access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN, PHARMA US, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Issues realted to public health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Issues related to immigration policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · Q2
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · RR
Patient access to digital health innovation
CURRENT CLINIC INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · RA
Medicare payment for cardiac procedures
CABALETTA BIO via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Cell and gene therapy innovation and access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Healthcare claims adjudication
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIC ASSOCIATES via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · second_quarter · RR
Advocate on access to pediatric medical care for children
CURRENT CLINIC INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · RR
Medicare payment for cardiac procedures
ESSENTIA HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN, PHARMA US, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Issues realted to public health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.
Issues related to immigration policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF ACOS via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · 1T
Represent the company in advocacy including congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALLADIAN PARTNERS, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · 1T
National Institutes of Health - All of Us - program and education
Congressional appropriations and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLEO HEALTH via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · Q1
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABALETTA BIO via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · RR
Specific lobbying issues: Cell and gene therapy innovation and access
FEDERAL HEARINGS AND APPEALS SERVICES, INC. via HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 · first_quarter · RR
b.Specific lobbying issues: Healthcare claims adjudication
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma- derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the role of biotechnology in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN, PHARMA US, INC. via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Issues realted to public health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF ACOS via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Represent the company in advocacy including congressional and regulatory affairs
SOLEO HEALTH via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALLADIAN PARTNERS, INC. via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Congressional appropriations and funding
National Institutes of Health - All of Us - program and education
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSENTIA HEALTH via HOGAN LOVELLS US LLP
2024 · fourth_quarter · Q4
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSENTIA HEALTH via HOGAN LOVELLS US LLP
2024 · third_quarter · 3A
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Healthcare access and workforce
Healthcare access and workforce
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSENTIA HEALTH via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Legislative advice and advocacy related to health policy and federal funding for health care services.
Filing targets: SENATE
SOLEO HEALTH via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Represent the company in advocacy, includign congressional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF ACOS via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Represent the company in advocacy including congresional and regulatory affairs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGEND BIOTECH CORPORATION via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Advance Legend Biotech's interests with respect to educating member of Congress on the importance of the rol of biotechnology in heathcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Regulations pertaining to Radiologist Assistants (RAs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AI HEALTHCARE COALITION via HOGAN LOVELLS US LLP
2024 · third_quarter · Q3
Advocate on issues concerning health care and artificial intelligence technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE